Page 11234..1020..»

Galapagos creates new subscription right plan

By Dr. Matthew Watson

Mechelen, Belgium; 13 January 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 30,000 subscription rights under a new employee subscription right plan.

Read more:
Galapagos creates new subscription right plan

To Read More: Galapagos creates new subscription right plan
categoriaGlobal News Feed commentoComments Off on Galapagos creates new subscription right plan | dataJanuary 18th, 2022
Read All

REPEAT — Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading…

By Dr. Matthew Watson

-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed-

View original post here:
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading...

To Read More: REPEAT — Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading…
categoriaGlobal News Feed commentoComments Off on REPEAT — Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading… | dataJanuary 18th, 2022
Read All

Veranome Biosystems and Cold Spring Harbor Laboratory Enter Collaboration and Licensing Agreement to Develop Advanced In-Situ Sequencing Technologies

By Dr. Matthew Watson

MOUNTAIN VIEW, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Veranome Biosystems LLC announced today that it has entered a collaboration and licensing agreement with Cold Spring Harbor Laboratory (CSHL) that adds in-situ sequencing technology to Veranome’s spatial omics portfolio. Veranome now has one of the most comprehensive portfolios of assay technologies that can allow targeted mapping of cellular spatial gene expressions with multiplexed in-situ hybridization (ISH) as well as de-novo profiling of cellular transcripts using in-situ sequencing. The expanded assay portfolio coupled with Veranome’s advanced imaging capabilities will enable customers to explore a broad range of applications, including characterization of cell and gene therapies methods and CRISPR screens. Veranome will further develop these high-sensitivity assay chemistries to offer researchers the ability to profile archival FFPE tissue blocks with the same spatial resolution as fresh frozen samples when analyzed on Veranome’s Spatial Analyzer.

Read more from the original source:
Veranome Biosystems and Cold Spring Harbor Laboratory Enter Collaboration and Licensing Agreement to Develop Advanced In-Situ Sequencing Technologies

To Read More: Veranome Biosystems and Cold Spring Harbor Laboratory Enter Collaboration and Licensing Agreement to Develop Advanced In-Situ Sequencing Technologies
categoriaGlobal News Feed commentoComments Off on Veranome Biosystems and Cold Spring Harbor Laboratory Enter Collaboration and Licensing Agreement to Develop Advanced In-Situ Sequencing Technologies | dataJanuary 18th, 2022
Read All

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

By Dr. Matthew Watson

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

See original here:
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

To Read More: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
categoriaGlobal News Feed commentoComments Off on Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China | dataJanuary 18th, 2022
Read All

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics…

By Dr. Matthew Watson

Live webcast will be at 8:30 a.m. EST on January 25 Live webcast will be at 8:30 a.m. EST on January 25

Read the original post:
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics...

To Read More: Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics…
categoriaGlobal News Feed commentoComments Off on Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics… | dataJanuary 18th, 2022
Read All

Lowell Farms Welcomes Jeff Monat to Board of Directors

By Dr. Matthew Watson

California-based cannabis leader adds veteran finance executive and investor to leadership team California-based cannabis leader adds veteran finance executive and investor to leadership team

Read more:
Lowell Farms Welcomes Jeff Monat to Board of Directors

To Read More: Lowell Farms Welcomes Jeff Monat to Board of Directors
categoriaGlobal News Feed commentoComments Off on Lowell Farms Welcomes Jeff Monat to Board of Directors | dataJanuary 18th, 2022
Read All

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

By Dr. Matthew Watson

Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

View post:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

To Read More: Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
categoriaGlobal News Feed commentoComments Off on Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | dataJanuary 18th, 2022
Read All

Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

By Dr. Matthew Watson

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile

More here:
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

To Read More: Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.
categoriaGlobal News Feed commentoComments Off on Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A. | dataJanuary 18th, 2022
Read All

LIDDS presents at Redeye Fight Cancer Seminar

By Dr. Matthew Watson

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will participate at Redeye Fight Cancer Seminar on January 20, 2022.

Read the original:
LIDDS presents at Redeye Fight Cancer Seminar

To Read More: LIDDS presents at Redeye Fight Cancer Seminar
categoriaGlobal News Feed commentoComments Off on LIDDS presents at Redeye Fight Cancer Seminar | dataJanuary 18th, 2022
Read All

Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

By Dr. Matthew Watson

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.

Read more:
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

To Read More: Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference
categoriaGlobal News Feed commentoComments Off on Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference | dataJanuary 18th, 2022
Read All

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

By Dr. Matthew Watson

— Meeting to Reconvene on January 18, 2022 —

Continue reading here:
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

To Read More: Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
categoriaGlobal News Feed commentoComments Off on Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders | dataJanuary 18th, 2022
Read All

NRx Responds to Relief’s Allegations of January 14, 2022

By Dr. Matthew Watson

RADNOR, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, responded to today’s press release issued by Relief Therapeutics.

More here:
NRx Responds to Relief’s Allegations of January 14, 2022

To Read More: NRx Responds to Relief’s Allegations of January 14, 2022
categoriaGlobal News Feed commentoComments Off on NRx Responds to Relief’s Allegations of January 14, 2022 | dataJanuary 18th, 2022
Read All

Novo Nordisk announces settlement of securities lawsuit in Denmark

By Dr. Matthew Watson

Bagsværd, Denmark, 14 January 2022 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs.

Go here to read the rest:
Novo Nordisk announces settlement of securities lawsuit in Denmark

To Read More: Novo Nordisk announces settlement of securities lawsuit in Denmark
categoriaGlobal News Feed commentoComments Off on Novo Nordisk announces settlement of securities lawsuit in Denmark | dataJanuary 18th, 2022
Read All

John Dawson to retire from Oxford Biomedica

By Dr. Matthew Watson

John Dawson to retire from Oxford Biomedica

Go here to read the rest:
John Dawson to retire from Oxford Biomedica

To Read More: John Dawson to retire from Oxford Biomedica
categoriaGlobal News Feed commentoComments Off on John Dawson to retire from Oxford Biomedica | dataJanuary 18th, 2022
Read All

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

By Dr. Matthew Watson

NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer. Dominique Costantini, current Chairwoman of OSE Immunotherapeutics’ Board of Directors, and previously CEO from 2012 to 2018, has been appointed interim Chief Executive Officer, effective immediately. A search for a new CEO has been launched with the assistance of a leading executive search firm.

View original post here:
OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

To Read More: OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles
categoriaGlobal News Feed commentoComments Off on OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles | dataJanuary 18th, 2022
Read All

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

By Dr. Matthew Watson

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.

Go here to see the original:
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

To Read More: Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
categoriaGlobal News Feed commentoComments Off on Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases | dataJanuary 18th, 2022
Read All

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

By Dr. Matthew Watson

IRB approval to initiate Phase 2 study for methamphetamine abuse disorders

Read more:
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

To Read More: Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
categoriaGlobal News Feed commentoComments Off on Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs | dataJanuary 18th, 2022
Read All

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

By Dr. Matthew Watson

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

See the original post here:
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

To Read More: Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
categoriaGlobal News Feed commentoComments Off on Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill | dataJanuary 18th, 2022
Read All

Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

By Dr. Matthew Watson

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022 Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022

The rest is here:
Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

To Read More: Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee
categoriaGlobal News Feed commentoComments Off on Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee | dataJanuary 18th, 2022
Read All

Sanofi: Information concerning the total number of voting rights and shares – December 2021

By Dr. Matthew Watson

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Read the original post:
Sanofi: Information concerning the total number of voting rights and shares – December 2021

To Read More: Sanofi: Information concerning the total number of voting rights and shares – December 2021
categoriaGlobal News Feed commentoComments Off on Sanofi: Information concerning the total number of voting rights and shares – December 2021 | dataJanuary 18th, 2022
Read All

Page 11234..1020..»